JPRN-UMIN000011086已完成未知
Evaluation of the safety and efficacy of transgenic rice containing peptides from Japanese cedar pollen allergens. - Evaluation of the safety and efficacy of transgenic rice containing peptides from Japanese cedar pollen allergens.
The Jikei University, School of Medicine0 个研究点目标入组 43 人开始时间: 2013年7月1日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 43
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) A person who is allergic to Rice or has a history of Rice allergy. 2) A person who shows Pet/House dust specific IgE antibody valued over Class V, and has pet (dogs and cats). 3) A person who is imperative to use medicine such as anti-allergic agent and steroidal chemicals that potentially influence the outcome of evaluation. 4) A person who underwent an operation that is accompanied to nasal disorder within last 2years, or has nasal disorder such as acute/chronic-rhinitis, rhinopolypus, hypertronic rhinitis, septal deviation, sinusitis which all are potentially hinder to the outcome of evaluation. 5) A person who ever received immunotherapy in the past. 6) A person who has any disorders under treatment and the condition is unstable that trial investigator has asessed as mismatched participant. 7) A person who has a history of serious disorder such as diabetes, hepatic disorder, kidney disorder, and cardiac disorder. 8) A person who takes beta-blocker in order to treat complecating disorders such as hypertension, and / or cardiac disorder. 9) A person who takes alpha-blocker in order to treat complecating disorders such as prostatic hyperplasia. 10) A person who is complecated by immunodeficiency disorder, cancer, or severe enemia. 11) A person who is complecated by severe asthma. 12) A person who'S pre-clinical test showed AST(GOT), ALT(GRT), Creatinine or BUN value exceed 1.5 times the upper limit or normal, or has other laboratory abonormalities that trial investigator has assessed as mismatched participant. 13) A person who participates in other clinical test at the onset of this test. 14) A person who is presently breastfeeding, pregnant, or planning/wishing to be a pregnant during a period of this clinical test. 15) A person whom trial investigator has asessed as mismatched participant.
研究者
相似试验
进行中（未招募）
1 期
Prospective study on safety and efficacy of gene therapy with voretigene neparvovec (Luxturna®) in patients with RPE65-associated inherited retinal degenerationsEUCTR2021-000265-33-NLThe Rotterdam Eye Hospital20
尚未招募
不适用
Prospective study on safety and efficacy of gene therapy with voretigene neparvovec (Luxturna®) in patients with RPE65-associated inherited retinal degenerationsRPE65-associated inherited retinal degenerations (IRDs).NL-OMON22976The Rotterdam Eye Hospital20
招募中
不适用
Prospective study on safety and efficacy of gene therapy with voretigene neparvovec (Luxturna®) in patients with RPE65-associated inherited retinal degenerationsRPE65-associated inherited retinal degenerations10010463NL-OMON50929Oogziekenhuis Rotterdam20
已完成
2 期
ior ®EPOCIM as a cardioprotective agent in the surgery of rheumatic valvular disease.Rheumatic valvular diseaseRPCEC00000165Center of Molecular Immunology (CIM), Havana30
已完成
不适用
Safety and preliminary protective efficacy of genetically attenuated Pf*mei2 (GA2) malaria parasites in healthy Dutch volunteersparasitaire ziekte10037072MalariaNL-OMON51062eids Universitair Medisch Centrum51